Short and medium chain acylcarnitines as markers of outcome in diabetic and non-diabetic subjects with acute coronary syndromes

Davies, Allan; Wenzl, Florian A; Li, Xinmin S; Winzap, Patric; Obeid, Slayman; Klingenberg, Roland; Mach, François; Räber, Lorenz; Muller, Olivier; Matter, Christian M; Laaksonen, Reijo; Wang, Zeneng; Hazen, Stanley L; Lüscher, Thomas F

doi:10.1016/j.ijcard.2023.131261

Citations

Citation copied

Davies, A., Wenzl, F. A., Li, X. S., Winzap, P., Obeid, S., Klingenberg, R., Mach, F., Räber, L., Muller, O., Matter, C. M., Laaksonen, R., Wang, Z., Hazen, S. L., & Lüscher, T. F. (2023). Short and medium chain acylcarnitines as markers of outcome in diabetic and non-diabetic subjects with acute coronary syndromes. International Journal of Cardiology, 389, 131261. https://doi.org/10.1016/j.ijcard.2023.131261

Abstract

Background: Carnitine metabolism produces numerous molecular species of short-, medium-, and long-chain acylcarnitines, which play important roles in energy homeostasis and fatty acid transport in the myocardium. Given that disturbances in the carnitine metabolism are linked to cardiometabolic disease, we studied the relationship of circulating acylcarnitines with outcomes in patients with acute coronary syndromes (ACS) and evaluated differences in circulating levels of these metabolites between diabetic and non-diabetic patients.

Me